Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 17;12(8):1022-31.
doi: 10.7150/ijbs.15438. eCollection 2016.

A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Yi Li  1 , Ji Wang  2 , Xiaowei Ma  3 , Li Tan  3 , Yanli Yan  3 , Chaofan Xue  3 , Beina Hui  4 , Rui Liu  4 , Hailin Ma  4 , Juan Ren  4
Affiliations
Review

A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Yi Li et al. Int J Biol Sci. .

Abstract

Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy not only can reduce tumor size and recurrence, but also increase the tumor resection rate and anus retention rate with very slight side effect. Comparing with preoperative chemotherapy, preoperative chemoradiotherapy can further reduce the local recurrence rate and downstage. Middle and low rectal cancers can benefit more from neoadjuvant chemradiotherapy than high rectal cancer. It needs to refine the selection of appropriate patients and irradiation modes for neoadjuvant chemoradiotherapy. Different therapeutic reactions to neoadjuvant chemoradiotherapy affect the type of surgical techniques, hence calling for the need of much attention. Furthermore, many problems such as accurate staging before surgery, selection of suitable neoadjuvant chemoradiotherapy method, and sensitivity prediction to preoperative radiotherapy need to be well settled.

Keywords: Rectal cancer; preoperative concurrent chemoradiotherapy.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

References

    1. Lemmens V, Steenbergen LV, Janssenheijnen M, Martijn H, Rutten H, Coebergh JW. Trends in colorectal cancer in the south of the Netherlands 1975-2007: Rectal cancer survival levels with colon cancer survival. Acta Oncol. 2010;49:784–96. - PubMed
    1. Glimelius B, editor Multidisciplinary treatment of patients with rectal cancer. Development during the past decades and plans for the future. Mechatronics and Automation (ICMA), 2012 International Conference on; 2012. - PMC - PubMed
    1. Hwang K, Park IJ, Chang SY, Lim SB, Lee JL, Yong SY, Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer. World J Gastroenterology; 2015. pp. 555–62. - PMC - PubMed
    1. Brændengen M, Tveit KM, Berglund Å, Birkemeyer E, Frykholm G, Påhlman L. et al. Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer. J Clinical Oncology. 2008;26:3687–94. - PubMed
    1. R S, H B, W H, C R, C W, R F. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. New Engl J Med. 2004;351:1731–40. - PubMed